Identification of urinary proteins potentially associated with diabetic kidney disease

Indian Journal of Nephrology

Volumn 26, Issue 6, 2016, Pages 434-445

  Marikanty, R K ^a   Gupta, M K ^a,b   Cherukuvada, S V B ^a   Kompella, S S S ^a   Prayaga, A K ^a   Konda, S ^a   Polisetty, R V ^a   Idris, M M ^a   Rao, P M ^a   Chandak, G R ^a   Dakshinamurty, K V ^a  

^a NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

^b International Tech Park Ltd   (India)

Author keywords

Biomarker; diabetic nephropathy; liquid chromatography tandem mass spectrometry; microalbuminuria; Orbitrap; urinary proteomics

Indexed keywords

ALBUMIN; ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 2 ANTIPLASMIN; CD2 ASSOCIATED PROTEIN; CD59 ANTIGEN; COMPLEMENT FACTOR H; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYSTATIN B; DESMOGLEIN 2; DIPEPTIDYL PEPTIDASE I; EXTRACELLULAR MATRIX PROTEIN 1; FETUIN A; FIBRINOGEN; GALECTIN 3; GASTRICSIN; GLYCOPROTEIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN BETA 2; KALLIKREIN; KININOGEN; LUMICAN; MYOGLOBIN; PEPTIDE; PLASMA PROTEIN; PREALBUMIN; PROTEOME; SCLEROPROTEIN; SYNAPSIN I; TRYPSIN; UNCLASSIFIED DRUG; VITAMIN D BINDING PROTEIN;

ADULT; ARTICLE; BLOOD CLOTTING; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; FEMALE; HUMAN; MACROALBUMINURIA; MALE; MASS SPECTROMETRY; MESANGIUM CELL; MICROALBUMINURIA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN URINE LEVEL; REVERSED PHASE LIQUID CHROMATOGRAPHY; URINE SAMPLING;

EID: 84996588160     PISSN: 09714065     EISSN: 19983662     Source Type: Journal    
DOI: 10.4103/0971-4065.176144     Document Type: Article

References (49)

1. Sicree R, Shaw J, Zimmet P. Diabetes and impaired glucose tolerance. In: Gan D, editor. Diabetes Atlas. 3 rd ed. Kortrijik (Heule), Belgium: International Diabetes Federation; 2006. p. 15-103
2. Chacko B, Vincent L. Prevalence of diabetic nephropathy. In: Dakshinamurty KV, editor. Diabetic Kidney Disease: Clinical Update in Nephrology. India: Elsevier; 2011. p. 85-115
3. Ben Ameur R, Molina L, Bolvin C, Kifagi C, Jarraya F, Ayadi H, et al. Proteomic approaches for discovering biomarkers of diabetic nephropathy. Nephrol Dial Transplant 2010;25:2866-75
4. Thongboonkerd V, McLeish KR, Arthur JM, Klein JB. Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int 2002;62:1461-9
5. Sharma K, Lee S, Han S, Lee S, Francos B, McCue P, et al. Two-dimensional fluorescence difference gel electrophoresis analysis of the urine proteome in human diabetic nephropathy. Proteomics 2005;5:2648-55
6. Lafitte D, Dussol B, Andersen S, Vazi A, Dupuy P, Jensen ON, et al. Optimized preparation of urine samples for two-dimensional electrophoresis and initial application to patient samples. Clin Biochem 2002;35:581-9
7. Jain S, Rajput A, Kumar Y, Uppuluri N, Arvind AS, Tatu U. Proteomic analysis of urinary protein markers for accurate prediction of diabetic kidney disorder. J Assoc Physicians India 2005;53:513-20
8. Otu HH, Can H, Spentzos D, Nelson RG, Hanson RL, Looker HC, et al. Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care 2007;30:638-43
9. Meier M, Kaiser T, Herrmann A, Knueppel S, Hillmann M, Koester P, et al. Identification of urinary protein pattern in type 1 diabetic adolescents with early diabetic nephropathy by a novel combined proteome analysis. J Diabetes Complications 2005;19:223-32
10. Rossing K, Mischak H, Parving HH, Christensen PK, Walden M, Hillmann M, et al. Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. Kidney Int 2005;68:193-205
11. Kim HJ, Cho EH, Yoo JH, Kim PK, Shin JS, Kim MR, et al. Proteome analysis of serum from type 2 diabetics with nephropathy. J Proteome Res 2007;6:735-43
12. Rao PV, Reddy AP, Lu X, Dasari S, Krishnaprasad A, Biggs E, et al. Proteomic identification of salivary biomarkers of type-2 diabetes. J Proteome Res 2009;8:239-45
13. Rao PV, Lu X, Standley M, Pattee P, Neelima G, Girisesh G, et al. Proteomic identification of urinary biomarkers of diabetic nephropathy. Diabetes Care 2007;30:629-37
14. Rossing K, Mischak H, Dakna M, Zürbig P, Novak J, Julian BA, et al. Urinary proteomics in diabetes and CKD. J Am Soc Nephrol 2008;19:1283-90
15. Andersen S, Mischak H, Zürbig P, Parving HH, Rossing P. Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria. BMC Nephrol 2010;11:29
16. Lapsley M, Flynn FV, Sansom PA. Beta 2-glycoprotein-1 (apolipoprotein H) excretion and renal tubular malfunction in diabetic patients without clinical proteinuria. J Clin Pathol 1993;46:465-9
17. Riaz S, Alam SS, Srai SK, Skinner V, Riaz A, Akhtar MW. Proteomic identification of human urinary biomarkers in diabetes mellitus type 2. Diabetes Technol Ther 2010;12:979-88
18. Goligorsky MS, Addabbo F, O′Riordan E. Diagnostic potential of urine proteome: A broken mirror of renal diseases. J Am Soc Nephrol 2007;18:2233-9
19. Groop L, Mäkipernaa A, Stenman S, DeFronzo RA, Teppo AM. Urinary excretion of kappa light chains in patients with diabetes mellitus. Kidney Int 1990;37:1120-5
20. Mykkänen L, Haffner SM, Kuusisto J, Pyorälä K, Laakso M. Microalbuminuria precedes the development of NIDDM. Diabetes 1994;43:552-7
21. Thongboonkerd V. Study of diabetic nephropathy in the proteomic era. Contrib Nephrol 2011;170:172-83
22. Rodriguez-Suarez E, Siwy J, Zurbig P, Mischak H. Urine as a source for clinical proteome analysis: From discovery to clinical application. Biochim Biophys Acta 2014;1844:884-98
23. Bellei E, Rossi E, Lucchi L, Uggeri S, Albertazzi A, Tomasi A, et al. Proteomic analysis of early urinary biomarkers of renal changes in type 2 diabetic patients. Proteomics Clin Appl 2008;2:478-91
24. Mehrotra R, Westenfeld R, Christenson P, Budoff M, Ipp E, Takasu J, et al. Serum fetuin-A in nondialyzed patients with diabetic nephropathy: Relationship with coronary artery calcification. Kidney Int 2005;67:1070-7
25. Kumar Y, Uppuluri NR, Babu K, Phadke K, Kumar P, Ballal S, et al. Proteomics of renal disorders: Urinary proteome analysis by two-dimensional gel electrophoresis and MALDI-TOF mass spectrometry. Curr Sci India 2002;82:655-63
26. Varghese SA, Powell TB, Budisavljevic MN, Oates JC, Raymond JR, Almeida JS, et al. Urine biomarkers predict the cause of glomerular disease. J Am Soc Nephrol 2007;18:913-22
27. Van Campenhout A, Van Campenhout C, Lagrou AR, Abrams P, Moorkens G, Van Gaal L, et al. Impact of diabetes mellitus on the relationships between iron-, inflammatory-and oxidative stress status. Diabetes Metab Res Rev 2006;22:444-54
28. Bakker WW, Borghuis T, Harmsen MC, van den Berg A, Kema IP, Niezen KE, et al. Protease activity of plasma hemopexin. Kidney Int 2005;68:603-10
29. Szathmary EJ. The effect of Gc genotype on fasting insulin level in Dogrib Indians. Hum Genet 1987;75:368-72
30. Iyengar S, Hamman RF, Marshall JA, Majumder PP, Ferrell RE. On the role of Vitamin D binding globulin in glucose homeostasis: Results from the San Luis Valley Diabetes Study. Genet Epidemiol 1989;6:691-8
31. Baier LJ, Dobberfuhl AM, Pratley RE, Hanson RL, Bogardus C. Variations in the Vitamin D-binding protein (Gc locus) are associated with oral glucose tolerance in nondiabetic Pima Indians. J Clin Endocrinol Metab 1998;83:2993-6
32. Hirai M, Suzuki S, Hinokio Y, Chiba M, Kasuga S, Hirai A, et al. Group specific component protein genotype is associated with NIDDM in Japan. Diabetologia 1998;41:742-3
33. Kuoppala T. Alterations in Vitamin D metabolites and minerals in diabetic pregnancy. Gynecol Obstet Invest 1988;25:99-105
34. Nahman NS. Mesangial cell responses to high glucose-levels and the development of diabetic glomerulosclerosis. Nefrologia 1994;14:385-90
35. Ha H, Lee HB. Reactive oxygen species amplify glucose signalling in renal cells cultured under high glucose and in diabetic kidney. Nephrology (Carlton) 2005;10 Suppl: S7-10
36. Moreno-Navarrete JM, Martínez-Barricarte R, Catalán V, Sabater M, Gómez-Ambrosi J, Ortega FJ, et al. Complement factor H is expressed in adipose tissue in association with insulin resistance. Diabetes 2010;59:200-9
37. Roy A, Sen S, Chakraborti AS. In vitro nonenzymatic glycation enhances the role of myoglobin as a source of oxidative stress. Free Radic Res 2004;38:139-46
38. Riad A, Zhuo JL, Schultheiss HP, Tschöpe C. The role of the renal kallikrein-kinin system in diabetic nephropathy. Curr Opin Nephrol Hypertens 2007;16:22-6
39. Miyata T, Jadoul M, Kurokawa K, Van Ypersele de Strihou C. Beta-2 microglobulin in renal disease. J Am Soc Nephrol 1998;9:1723-35
40. Alkhalaf A, Zürbig P, Bakker SJ, Bilo HJ, Cerna M, Fischer C, et al. Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS One 2010;5:e13421
41. Benigni A, Gagliardini E, Tomasoni S, Abbate M, Ruggenenti P, Kalluri R, et al. Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. Kidney Int 2004;65:2193-200
42. Li C, Ruotsalainen V, Tryggvason K, Shaw AS, Miner JH. CD2AP is expressed with nephrin in developing podocytes and is found widely in mature kidney and elsewhere. Am J Physiol Renal Physiol 2000;279:F785-92
43. Shih NY, Li J, Karpitskii V, Nguyen A, Dustin ML, Kanagawa O, et al. Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science 1999;286:312-5
44. Zheng M, Lv LL, Ni J, Ni HF, Li Q, Ma KL, et al. Urinary podocyte-associated mRNA profile in various stages of diabetic nephropathy. PLoS One 2011;6:e20431
45. Lehr S, Hartwig S, Lamers D, Famulla S, Müller S, Hanisch FG, et al. Identification and validation of novel adipokines released from primary human adipocytes. Mol Cell Proteomics 2012;11. Doi: 10. 1074/mcp. M111. 010504
46. Qin X, Goldfine A, Krumrei N, Grubissich L, Acosta J, Chorev M, et al. Glycation inactivation of the complement regulatory protein CD59: A possible role in the pathogenesis of the vascular complications of human diabetes. Diabetes 2004;53:2653-61
47. Wu G, Hu W, Shahsafaei A, Song W, Dobarro M, Sukhova GK, et al. Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex. Circ Res 2009;104:550-8
48. Acosta J, Hettinga J, Flückiger R, Krumrei N, Goldfine A, Angarita L, et al. Molecular basis for a link between complement and the vascular complications of diabetes. Proc Natl Acad Sci U S A 2000;97:5450-5
49. Gasque P. Complement: A unique innate immune sensor for danger signals. Mol Immunol 2004;41:1089-98.